Study Assesses Sarilumab for Polymyalgia Rheumatica

In an ACR Convergence 2022 session, Robert Spiera, MD, director of the Scleroderma, Vasculitis, and Myositis Center at the Hospital for Special Surgery, New York City, discussed the use of sarilumab as a potential glucocorticoid-sparing therapy in a phase 3 study in patients with treatment-refractory polymyalgia rheumatica (PMR), one of the most common inflammatory diseases...

Source: The Rheumatologist - January 25, 2024 Category: Rheumatology Authors: Ruth Jessen Hickman, MD Tags: Biologics/DMARDs Conditions Drug Updates Other Rheumatic Conditions Research Rheum IL-6 IL-6 inhibitors PMR FocusRheum Polymyalgia Rheumatica Research Review sarilumab steroid-sparing therapies Source Type: research